Literature DB >> 19433015

Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke.

Veronique Guyomard1, Phyo Kyaw Myint.   

Abstract

Stroke is the most common cause of disability and a major cause of mortality. Each year, more than 500,000 Americans sustain a stroke. Reperfusion and antithrombotic therapies are still of limited benefit, hence increasing interest has been focused on therapeutic approaches that prevent and/or modulate infarct evolution. Hyperglycemia in acute stroke has a poor prognosis and is associated with significant morbidity and mortality. However, it remains unclear whether intensive lowering of blood glucose levels in the hyperacute and acute phases of stroke improves clinical outcomes. Experimental data suggest that elevated blood glucose may contribute to infarct expansion directly through a number of maladaptive metabolic pathways and that treatment with insulin may attenuate these adverse effects. Despite some controversy surrounding the optimal level of blood glucose control, much of the evidence to date supports rigorous blood glucose control and comprehensive cardiovascular risk factor management to prevent stroke in patients with diabetes. The current recommendation is to aim for strict control of blood pressure, glucose, and lipids along with lifestyle modification to improve cardiovascular health. However, there remains a distinct paucity of information concerning secondary stroke prevention. To date, the overwhelming evidence suggests that aggressive glucose management should be the standard of care in all patients with stroke and hyperglycemia. This article presents an overview of the recommendations for the optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke.

Entities:  

Year:  2009        PMID: 19433015     DOI: 10.1007/s11936-009-0021-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  27 in total

1.  Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes.

Authors:  Neil Munro; Michael D Feher
Journal:  Br J Gen Pract       Date:  2008-08       Impact factor: 5.386

2.  Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.

Authors:  Theodore Mazzone
Journal:  Am J Med       Date:  2007-09       Impact factor: 4.965

3.  Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

Authors:  G Howard; R Bergman; L E Wagenknecht; S M Haffner; P J Savage; M F Saad; A Laws; R B D'Agostino
Journal:  Ann Epidemiol       Date:  1998-08       Impact factor: 3.797

4.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

Review 5.  Sirtuins: novel targets for metabolic disease in drug development.

Authors:  Wei-jian Jiang
Journal:  Biochem Biophys Res Commun       Date:  2008-06-23       Impact factor: 3.575

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

9.  [The effect of medicamentous and non-medicamentous therapy on lowering risk factors for cardiovascular and cerebrovascular episodes in an interventional study].

Authors:  Mirjana Lapcević; Mira Vuković; Ivan Dimitrijević; Nevena Kalezić; Jelena Ristić
Journal:  Srp Arh Celok Lek       Date:  2007 Sep-Oct       Impact factor: 0.207

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.